Navitoclax
Showing 26 - 40 of 40
Platinum-resistant or Refractory Ovarian Cancer Trial in France (ABT-263)
Completed
- Platinum-resistant or Refractory Ovarian Cancer
-
Besançon, France
- +15 more
Mar 15, 2019
Prostate Cancer Trial in New Brunswick (Abiraterone, ABT-263, Hydroxychloroquine)
Terminated
- Prostate Cancer
- Abiraterone
- +2 more
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Mar 30, 2017
Small Cell Lung Cancer, Small Cell Lung Carcinoma Trial in Canada, United Kingdom, United States (ABT-263)
Completed
- Small Cell Lung Cancer
- Small Cell Lung Carcinoma
-
Peoria, Arizona
- +17 more
Jun 1, 2018
DLBCL Trial in United States (bendamustine, navitoclax, rituximab)
Withdrawn
- Diffuse Large B-Cell Lymphoma
- bendamustine
- +2 more
-
Fountain Valley, California
- +12 more
Nov 1, 2016
Chronic Lymphocytic Leukemia Trial in Worldwide (Navitoclax)
Completed
- Chronic Lymphocytic Leukemia
- Navitoclax
-
La Jolla, California
- +14 more
Jul 2, 2014
Lymphoma, Chronic Lymphocytic Leukemia, Solid Tumors Trial in San Antonio (ABT-263, Ketoconazole)
Completed
- Lymphoma
- +2 more
-
San Antonio, TexasSite Reference ID/Investigator# 25068
Dec 16, 2010
Healthy Female Subjects Trial in Waukegan (ABT-263)
Completed
- Healthy Female Subjects
-
Waukegan, IllinoisSite Reference ID/Investigator# 23602
Nov 8, 2010